Group items tagged

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

More than 5,000 vulnerable people have enrolled for the ground-breaking Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) study on life-saving antivirals. With this the UK is now one step closer to rolling out the innovative medicines, which would help reduce the severity of symptoms and the risk of hospitalisation or death. Success of the study would eventually help to ease pressures on the NHS. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result.

IRRITABLE BOWEL SYNDROME,a very common condition affecting many and above all a very discomforting condition.It affects both men & women,but more commonly the females.Irritable bowel syndrome affects the large intestine or the colon.

https://misoprostolhotline.com/jual-cytotec/ Jual misoprostol cytotec makassar Jual Obat Cytotec di Bandung. call 08574 0559 466. by. misoprostolhotline

There is a medicine for it https://herbhomecure.com/dulcoflex-tablet-uses-in-hindi/

Any individual who has surfed over the internet must have come across one phrase'BUY VIAGRA'.I sometimes wonder whether we actually know what is viagra.Sildenafil has greatly improved the treatment of erectile dysfunction.This drug is effective in a broad range of causes of erectile dysfunction like diebetogenic[due to diabetes],vasculogenic

http://www.moderntimesindia.com/, Modern Times Helpline Pharma - Exporter of Gefitinib Medicines & Erlotinib Tablets from New Delhi

jual cytotec misoprostol makassar 085740559466 https://misoprostolhotline.com/

FlowForce Max is an innovative, natural and effective way to address your prostate problems, while adding your energy, libido, and vitality. An impeccably cured personal mix of precisely named plants and minerals, crafted and mixed to complement one another into an important prostate supporting formula. Produced in FDA- approved, GMP- certified installations, each bottle of this nutritive supplement comes with 30 tablets. So, if you follow the instructions given by the manufacturers, it also claims to be an each-natural, GMO-free supplement.